About Affimed (NASDAQ:AFMD)
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in Germany and internationally. Its lead candidate is AFM13, a natural killer cell (NK-cell) TandAb designed for the treatment of CD30-positive (CD30+) B- and T-cell malignancies, including Hodgkin lymphoma. The company's product candidates include AFM24, a NK-cell that treats epidermal growth factor receptor expressing solid tumors, such as lung, head, neck, and colon cancers; AFM26, which binds to B-cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific Abs for the treatment of multiple myeloma. Its product candidates also comprise AFM11, a T-cell TandAb, which is in Phase I clinical trial for the treatment of various CD19+ B-cell malignancies, including non-Hodgkin Lymphoma and acute lymphocytic leukemia; and AMV564, a CD33/CD3-specific T-cell TandAb for the treatment of acute myeloid leukemia and other hematologic malignancies. The company has license agreements with Amphivena Therapeutics, Inc., Deutsches Krebsforschungszentrum, and Xoma Ireland Limited; research funding agreement with The Leukemia & Lymphoma Society; and collaboration with Merck Sharp & Dohme B.V. It also has a clinical development and commercialization collaboration with The University of Texas MD Anderson Cancer Center to evaluate AFM13 in combination with MD Anderson's NK-cell product. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AFMD
CUSIPN/A
Phone49-62-2165-3070
Debt
Debt-to-Equity Ratio0.13%
Current Ratio5.61%
Quick Ratio5.58%
Price-To-Earnings
Trailing P/E Ratio-2.65
Forward P/E Ratio-3.01
P/E GrowthN/A
Sales & Book Value
Annual Sales$2.27 million
Price / Sales55.52
Cash FlowN/A
Price / CashN/A
Book Value$0.80 per share
Price / Book2.53
Profitability
EPS (Most Recent Fiscal Year)($0.78)
Net Income$-34,160,000.00
Net Margins-1,493.69%
Return on Equity-80.04%
Return on Assets-61.56%
Miscellaneous
Employees53
Outstanding Shares62,390,000
Affimed (NASDAQ:AFMD) Frequently Asked Questions
What is Affimed's stock symbol?
Affimed trades on the NASDAQ under the ticker symbol "AFMD."
How were Affimed's earnings last quarter?
Affimed (NASDAQ:AFMD) released its quarterly earnings data on Tuesday, March, 20th. The biopharmaceutical company reported ($0.16) EPS for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.16). The biopharmaceutical company earned $0.75 million during the quarter, compared to the consensus estimate of $0.56 million. Affimed had a negative return on equity of 80.04% and a negative net margin of 1,493.69%. View Affimed's Earnings History.
When is Affimed's next earnings date?
What price target have analysts set for AFMD?
3 equities research analysts have issued twelve-month target prices for Affimed's stock. Their forecasts range from $2.50 to $10.00. On average, they anticipate Affimed's stock price to reach $6.50 in the next year. View Analyst Ratings for Affimed.
Who are some of Affimed's key competitors?
Some companies that are related to Affimed include Athersys (ATHX), Bellicum Pharmaceuticals (BLCM), ArQule (ARQL), resTORbio (TORC), Ovid Therapeutics (OVID), Chimerix (CMRX), Ocular Therapeutix (OCUL), Viking Therapeutics (VKTX), Vital Therapies (VTL), Neos Therapeutics (NEOS), Synlogic (SYBX), Melinta Therapeutics (MLNT), Aratana Therapeutics (PETX), Molecular Templates (MTEM) and Ardelyx (ARDX).
Who are Affimed's key executives?
Affimed's management team includes the folowing people:
- Dr. Adi Hoess M.D., Ph.D., CEO, MD & Member of Management Board (Age 56)
- Dr. Florian H. M. Fischer MBA (Dipl.-Kfm.), Ph.D., MD, CFO & Member of Management Board (Age 50)
- Prof. Melvyn Little Ph.D., Founder and Consultant
- Dr. Wolfgang Fischer, Chief Operating Officer and Interim CMO
- Dr. Martin Treder, Chief Scientific Officer (Age 48)
Has Affimed been receiving favorable news coverage?
News articles about AFMD stock have trended somewhat positive on Monday, Accern Sentiment reports. Accern scores the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Affimed earned a daily sentiment score of 0.07 on Accern's scale. They also assigned media coverage about the biopharmaceutical company an impact score of 46.97 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future.
Who are Affimed's major shareholders?
How do I buy shares of Affimed?
Shares of AFMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Affimed's stock price today?
One share of AFMD stock can currently be purchased for approximately $2.02.
How big of a company is Affimed?
Affimed has a market capitalization of $127.90 million and generates $2.27 million in revenue each year. The biopharmaceutical company earns $-34,160,000.00 in net income (profit) each year or ($0.78) on an earnings per share basis. Affimed employs 53 workers across the globe.
How can I contact Affimed?
Affimed's mailing address is IM NEUENHEIMER FELD 582, HEIDELBERG 2M, 69120. The biopharmaceutical company can be reached via phone at 49-62-2165-3070 or via email at [email protected]
MarketBeat Community Rating for Affimed (AFMD)
MarketBeat's community ratings are surveys of what our community members think about Affimed and other stocks. Vote "Outperform" if you believe AFMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AFMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
Affimed (NASDAQ:AFMD) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
3 Wall Street analysts have issued ratings and price targets for Affimed in the last 12 months. Their average twelve-month price target is $6.50, suggesting that the stock has a possible upside of 221.78%. The high price target for AFMD is $10.00 and the low price target for AFMD is $2.50. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Hold | Buy |
| Consensus Rating Score: | 2.33 | 2.33 | 2.33 | 2.50 |
| Ratings Breakdown: | 0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $6.50 | $6.50 | $6.50 | $5.3750 |
| Price Target Upside: | 221.78% upside | 209.52% upside | 209.52% upside | 150.00% upside |
Affimed (NASDAQ:AFMD) Consensus Price Target History
Affimed (NASDAQ:AFMD) Analyst Ratings History
Show:
(Data available from 4/23/2016 forward)
Affimed (NASDAQ:AFMD) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Affimed (NASDAQ AFMD) Insider Trading and Institutional Ownership History
Institutional Ownership Percentage: 27.86%
Affimed (NASDAQ AFMD) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
(Data available from 1/1/2013 forward)
Affimed (NASDAQ AFMD) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Active-Investors: Blog Exposure - Preclinical Data Presented by Bayer at AACR Highlights Compugen's BAY 1905254 Efficacy in Cancer Immunotherapy
www.finanznachrichten.de - April 19 at 9:13 AM |
 | Affimed Presents Poster at AACR Highlighting Progress Toward Novel EGFR-targeting Therapy
finance.yahoo.com - April 16 at 4:34 PM |
 | Affimed (AFMD) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - April 12 at 4:31 PM |
| Affimed (AFMD) Upgraded to "Buy" at Zacks Investment Research
www.americanbankingnews.com - April 4 at 4:42 PM |
| Zacks Investment Research Upgrades Affimed (AFMD) to Buy
www.americanbankingnews.com - March 29 at 4:10 PM |
| Zacks Investment Research Lowers Affimed (AFMD) to Hold
www.americanbankingnews.com - March 28 at 4:25 PM |
| Q4 2018 Earnings Forecast for Affimed NV Issued By Jefferies Group (AFMD)
www.americanbankingnews.com - March 26 at 1:39 AM |
| Affimed (AFMD) Upgraded to Buy by Zacks Investment Research
www.americanbankingnews.com - March 23 at 4:34 PM |
| SunTrust Banks Equities Analysts Boost Earnings Estimates for Affimed NV (AFMD)
www.americanbankingnews.com - March 23 at 7:50 AM |
| Edited Transcript of AFMD earnings conference call or presentation 20-Mar-18 12:30pm GMT
finance.yahoo.com - March 21 at 10:21 AM |
| Affimed (AFMD) Issues Earnings Results
www.americanbankingnews.com - March 21 at 8:59 AM |
| Affimed N.V. to Host Earnings Call
finance.yahoo.com - March 20 at 9:29 AM |
| Has Affimed NV. (NASDAQ:AFMD) Improved Earnings Growth In Recent Times?
finance.yahoo.com - March 20 at 9:29 AM |
| Affimed Reports Financial Results for Fourth Quarter and Year End 2017
finance.yahoo.com - March 20 at 9:29 AM |
| Affimed Appoints Dr. Leila Alland as Chief Medical Officer
finance.yahoo.com - March 19 at 9:27 AM |
| Why Earnings Season Could Be Great for Affimed (AFMD)
finance.yahoo.com - March 19 at 9:27 AM |
| Affimed (AFMD) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - March 14 at 12:21 PM |
| Affimed NV. (NASDAQ:AFMD): When Will It Breakeven?
finance.yahoo.com - March 12 at 5:40 PM |
| $1.15 Million in Sales Expected for Affimed NV (AFMD) This Quarter
www.americanbankingnews.com - March 9 at 2:04 AM |
| Affimed NV (AFMD) Expected to Announce Earnings of -$0.17 Per Share
www.americanbankingnews.com - March 7 at 9:14 PM |
| Critical Comparison: Affimed (AFMD) & Molecular Templates (MTEM)
www.americanbankingnews.com - March 7 at 3:10 AM |
| Breaking Down Affimed NV.’s (NASDAQ:AFMD) Ownership Structure
finance.yahoo.com - February 22 at 4:57 PM |
| Brokerages Anticipate Affimed NV (AFMD) Will Post Quarterly Sales of $1.15 Million
www.americanbankingnews.com - February 21 at 12:21 PM |
| Is Affimed NV.’s (NASDAQ:AFMD) CEO Pay Justified?
finance.yahoo.com - February 15 at 4:42 PM |
| Affimed Announces Closing of Public Offering of Common Stock and Exercise of Underwriters' Option to Purchase Additional Shares
finance.yahoo.com - February 15 at 4:42 PM |
| Affimed Announces Proposed Public Offering of Common Stock
finance.yahoo.com - February 12 at 4:23 PM |
| Zacks: Brokerages Anticipate Affimed NV (AFMD) Will Announce Quarterly Sales of $1.15 Million
www.americanbankingnews.com - February 4 at 11:40 AM |
| Equities Analysts Issue Forecasts for Affimed NV's FY2022 Earnings (AFMD)
www.americanbankingnews.com - February 2 at 4:32 PM |
| Affimed NV (AFMD) Expected to Post Earnings of -$0.17 Per Share
www.americanbankingnews.com - February 2 at 5:16 AM |
| Affimed Reports New Data for AFM13 from Two Separate Clinical Trials in Hodgkin and CD30-Positive Lymphomas
finance.yahoo.com - February 1 at 9:21 AM |
| Should You Have Affimed NV’s (NASDAQ:AFMD) In Your Portfolio?
finance.yahoo.com - January 29 at 4:18 PM |
| Affimed NV (AFMD) Expected to Announce Quarterly Sales of $1.15 Million
www.americanbankingnews.com - January 18 at 10:30 AM |
| Affimed NV (NASDAQ:AFMD): Immense Growth Potential?
finance.yahoo.com - January 10 at 11:21 AM |
| Affimed N.V. (AFMD) Expected to Announce Quarterly Sales of $1.15 Million
www.americanbankingnews.com - December 15 at 2:56 PM |
| Did Affimed NV’s (NASDAQ:AFMD) Recent Earnings Growth Beat The Trend?
finance.yahoo.com - December 15 at 11:51 AM |
| Affirmed, Data Due in December, Potential Catalysts, Clinical Highlights
finance.yahoo.com - November 28 at 9:25 AM |
| Analysts Expect Affimed N.V. (AFMD) Will Post Quarterly Sales of $970,000.00
www.americanbankingnews.com - November 27 at 6:16 PM |
| Affimed's (AFMD) Hold Rating Reaffirmed at Oppenheimer Holdings, Inc.
www.americanbankingnews.com - November 27 at 1:14 PM |
| Analysts Anticipate Affimed N.V. (AFMD) to Announce -$0.18 Earnings Per Share
www.americanbankingnews.com - November 25 at 11:34 AM |
| FY2018 EPS Estimates for Affimed N.V. (AFMD) Increased by Analyst
www.americanbankingnews.com - November 10 at 5:40 PM |
| What Does Affimed NV’s (AFMD) Share Price Indicate?
finance.yahoo.com - November 10 at 4:10 PM |
| Affimed N.V. to Post Q1 2018 Earnings of ($0.20) Per Share, SunTrust Banks Forecasts (AFMD)
www.americanbankingnews.com - November 10 at 11:06 AM |
| Leerink Swann Comments on Affimed N.V.'s FY2017 Earnings (AFMD)
www.americanbankingnews.com - November 10 at 8:36 AM |
| Affimed NV :AFMD-US: Earnings Analysis: Q3, 2017 By the Numbers : November 8, 2017
finance.yahoo.com - November 8 at 5:46 PM |
| Affimed N.V. (AFMD) Expected to Post Quarterly Sales of $970,000.00
www.americanbankingnews.com - November 8 at 6:32 AM |
| Edited Transcript of AFMD earnings conference call or presentation 7-Nov-17 1:30pm GMT
finance.yahoo.com - November 7 at 10:12 PM |
| Affimed Reports Financial Results for Third Quarter 2017
finance.yahoo.com - November 7 at 5:08 PM |
| Affimed N.V. (AFMD) Releases Earnings Results, Beats Estimates By $0.03 EPS
www.americanbankingnews.com - November 7 at 1:58 PM |
| Brokerages Anticipate Affimed N.V. (AFMD) to Announce -$0.21 Earnings Per Share
www.americanbankingnews.com - November 6 at 3:08 PM |
| Affimed to Present Clinical and Preclinical Data on Immune Cell Engagers at ASH
finance.yahoo.com - November 1 at 3:58 PM |
Affimed (NASDAQ:AFMD) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Affimed (NASDAQ:AFMD) Income Statement, Balance Sheet and Cash Flow Statement
Affimed (NASDAQ AFMD) Stock Chart for Monday, April, 23, 2018
Loading chart…
